TITLE

Occult hepatitis B in high-risk patients needs more attention

AUTHOR(S)
Alavian, Seyed Moayed
PUB. DATE
February 2011
SOURCE
Journal of Infection in Developing Countries;Feb2011, Vol. 5 Issue 2, p149
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
65362713

 

Related Articles

  • Outcome of hemodialysis patients with occult hepatitis B virus infection at a 4 year follow-up. Ramezani, Amitis; Banifazl, Mohammad; Eslamifar, Ali; Ahmadi, Farrokhlagha; Razeghi, Effat; Aghakhani, Arezoo // Journal of Gastrointestinal & Liver Diseases;Mar2013, Vol. 22 Issue 1, p111 

    A letter to the editor is presented which discusses the study on patients' hemodialysis with occult hepatitis B virus infection (OBI) after a four year follow-up examination.

  • Adefovir Dipivoxil for Hepatitis B e Antigen—Positive Chronic Hepatitis B. Mukherjee, Sandeep // New England Journal of Medicine;6/12/2003, Vol. 348 Issue 24, p2468 

    A letter to the editor is presented in response to an article about the use of adefovir dipivoxil to treat hepatitis B by P. Marcellin and colleagues in February 27, 2003 issue.

  • Adefovir Dipivoxil for Hepatitis B e Antigen—Positive Chronic Hepatitis B. Marcellin, Patrick // New England Journal of Medicine;6/12/2003, Vol. 348 Issue 24, p2468 

    A response by Patrick Marcellin to a letter to the editor about his article on the use of adefovir dipivoxil to treat hepatitis B by P. Marcellin and colleagues in February 27, 2003 issue is presented.

  • Lamivudine in the Treatment of Polyarteritis Nodosa Associated with Acute Hepatitis B. Gupta, Samardeep; Piraka, Cyrus; Jaffe, Michele // New England Journal of Medicine;05/24/2001, Vol. 344 Issue 21, p1645 

    A letter to the editor is presented about the use of lamivudine in treating acute hepatitis B virus infection.

  • Treatment of HBeAg-Positive Hepatitis B with Peginterferon and Lamivudine. Song, Kenneth; Rajvanshi, Pankaj // New England Journal of Medicine;10/13/2005, Vol. 353 Issue 15, p1630 

    A letter to the editor is presented in response to the article "Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B," by G.K.K. Lau, T. Piratvisuth and K.X. Luo in the June 30, 2005 issue.

  • Treatment of HBeAg-Positive Hepatitis B with Peginterferon and Lamivudine. Orlent, Hans // New England Journal of Medicine;10/13/2005, Vol. 353 Issue 15, p1630 

    A letter to the editor is presented in response to the article "Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B," by G.K.K. Lau, T. Piratvisuth and K.X. Luo in the June 30, 2005 issue.

  • Treatment of HBeAg-Positive Hepatitis B with Peginterferon and Lamivudine. Lau, George K.K. // New England Journal of Medicine;10/13/2005, Vol. 353 Issue 15, p1630 

    A response by George K.K. Lau to several letters in response to his article "Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B" in the June 30, 2005 issue is presented.

  • Immunisation is most important strategy to control hepatitis B. Mansoor, Osman David; Wilson, Nick // BMJ: British Medical Journal (International Edition);1/22/2005, Vol. 330 Issue 7484, p197 

    Presents a letter to the editor in response to the article "Preventing and treating hepatitis B infection," by R. Aggarwal and P. Ranjan, in the November 6, 2004 issue.

  • High risk groups are still not being vaccinated. Winstock, Adam R. // BMJ: British Medical Journal (International Edition);1/22/2005, Vol. 330 Issue 7484, p198 

    Presents a letter to the editor in response to the article "Preventing and treating hepatitis B infection," by R. Aggarwal and P. Ranjan, in the November 6, 2004 issue.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics